Vaxcyte, Inc.

Vaxcyte, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Vaxcyte, Inc. has 144.79M shares outstanding.

As of June 30, 2026, Vaxcyte, Inc. maintains a current ratio of 5.72, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Vaxcyte, Inc. posted a negative return on equity (ROE) of -36.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.03, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 483.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Vaxcyte, Inc. generated - - in revenue and converted that into -931.55M in net income, yielding earnings per share of -6.76. EBITDA reached -996.54M, while operating income came in at -1.02B.

As of June 30, 2026, Vaxcyte, Inc. holds 1.30B in cash and equivalents against 101.05M in total debt, resulting in a net debt position of -160.35M. Total book value stands at 2.41B, with working capital of 1.12B providing operational flexibility.

Vaxcyte, Inc. produced -771.34M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -34.87M in capital expenditures, free cash flow totaled -806.21M - equivalent to -5.85 per share.